Antares Pharma, Inc. (ATRS) Release: Rapid Restoration And Consistent Maintenance Of Steady Blood Levels Achieved With Once-Weekly Subcutaneous Administration Of Testosterone Delivered With A Novel Auto Injector
6/25/2014 10:56:55 AM
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced the presentation of a scientific poster at the 16th International Congress of Endocrinology and the Endocrine Society’s 96th Annual Meeting & Expo held in Chicago, Illinois. The poster presents the final pharmacokinetic and safety results from 29 randomized patients treated with a once-weekly injection of testosterone administered subcutaneously with the Company’s VIBEX® QuickShot® auto injector. The Company’s previously reported interim results from this multi-center phase 2 clinical study were also presented as a scientific abstract at the same meeting.
Help employers find you! Check out all the jobs and post your resume.
comments powered by